DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)



company name or ticker

Salix' s Xifaxan 550 sNDA Under Review, Response by Feb 28 - Analyst Blog

Salix' s Xifaxan 550 sNDA Under Review, Response by Feb 28 - Analyst Blog

Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 20

Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting

AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog

How Will AstraZeneca (AZN) and Nektar Therapeutics (NKTR) Stock Reacy to FDA's Movantik Approval?

Nektar 181 Could Dominate A $13B Chronic Pain Market

Monday's ETF Movers: FBT, GDX

Positive Data on Baxter's Trial for BAX 855 - Analyst Blog

Positive Data on Baxter's Trial for BAX 855 - Analyst Blog

Nektar Therapeutics Has More To Give

Nektar Therapeutics Harnesses The Power Of AstraZeneca To Move Movantik

Nektar President Howard Robin Is Listening To You

See More Articles...